12 artigos
Uma revisão abrangente revela que falhas no controle de qualidade mitocondrial precedem o dano renal no diabetes, destacando alvos farmacológicos emergentes.
Novo estudo em camundongos revela que o CD38, e não a replicação viral em si, depleta o NAD+ cerebral durante a infecção pelo vírus Zika — apontando para um alvo farmacológico promissor.
Blocking CD38 with compound 78c replenishes NAD+, slashes inflammatory cytokines, and reduces oxidative stress in old macrophages infected with oral pathogens.
A landmark review reveals how declining NAD+ levels and disrupted circadian clocks form a vicious cycle driving dementia progression.
New research reveals how blocking CD38 boosts NAD+ levels, protecting retinal cells and offering a fresh therapeutic angle on glaucoma.
A comprehensive review reveals how the enzyme CD38 drives cardiovascular and neurological disease through calcium, NAD+, and inflammation signaling.
CD38 activity rises with age, depleting NAD+ and accelerating tissue decline. New research positions CD38 inhibitors as promising anti-aging therapeutics.
A new vaccination strategy targeting CD38 improved physical function, cognition, metabolism, and NAD+ levels in aging mice — with just a few injections.
A macrophage subset with high CD38 expression accelerates AKI-to-CKD progression by depleting NAD+, triggering tubular cell senescence and fibrosis.
A Harvard small molecule screen identified apigenin as a CD38 inhibitor, revealing how this common flavonoid raises cellular NAD levels.
A combinação de inibidores de CD38 e PD-1 produziu remissões duradouras em linfoma NK/células T recidivado, com duração mediana de resposta superior a 29 meses.
A selective CD38 inhibitor restores blood-brain barrier integrity and improves cognition in a mouse model of vascular dementia.
